Featured

Not Cullin it quits: removing CRL5 sustains T cell function in tumors

The lack of persistence after adoptive T cell therapies due to T cells becoming dysfunctional under chronic exposure to tumor antigens limits their efficacy. Two recent back-to-back publications by Bachl et al. and Saco et al. in Cancer Immunology Re...

Targeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity

Niu and Cheng et al. found that the RNA sensor MDA5 promoted tumor immune evasion by suppressing the unfolded protein response and the release of DAMPs associated with immunogenic cell death (ICD). Ta...

In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles

Chen, Monkovic, and Mughal et al. used NK cell receptor-specific scFvs to generate NK cell-targeted LNPs (NtLNPs) that transfected up to 80% of circulating and tissue NK cells, with minimal off-target...

Systemic antitumor responses to hypofractionated radiotherapy plus Poly(I:C) in advanced hepatocellular carcinoma: A phase 2 trial

In a phase 2 clinical trial in 37 patients with advanced HCC, Qiu et al. observed that adding s.c. Poly(I:C) to hypofractionated radiotherapy (HFRT) was well tolerated, and evaluable patients had bett...

Propionate promotes MHC class I antigen presentation and anti-tumor immunity

Li et al. found that dietary supplementation with the short-chain fatty acid propionate could be used to stabilize and maintain expression of MHC-I in tumor cells by binding to the E3 ligase STUB1, bl...

See all for this week

Previous Digests

New PrimeCAR protocol delivers improved CAR T cells in less time

October 21, 2026

CAR T cells are a powerful treatment option for certain cancers, but their use can be limited by long manufacturing times and severe toxicities. In order to overcome these hurdles, Yang and Li et al. developed a new CAR...

Checkpoints for the win: neoadjuvant ICB outperforms targeted therapy in melanoma

October 14, 2026

Neoadjuvant treatment with immunotherapy and/or targeted agents has become standard of care for resectable stage IIIB-D melanoma. However, the optimal treatment regimen and the consequences for long-term survival remain largely unknown. Long et al. analyzed a large dataset of...

T-RAP – a new tool for predicting TCR-pMHC reactivity

October 7, 2026

Predicting TCR-pMHC reactivity is useful for a variety of immunotherapy research tasks, including identifying relevant neoantigens and developing vaccines. In work recently published in Immunity, Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) and used...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials